Research graph
References from Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study
10.1016/s2214-109x(24)00355-3 · 2024 · External reference
Immunogenic cell death driven by radiation-impact on the tumor microenvironment
10.1007/978-3-030-38862-1_10 · 2020 · External reference
Radiotherapy, immunity, and immune checkpoint inhibitors
10.1016/s1470-2045(24)00075-5 · 2024 · External reference
Emerging evidence for adapting radiotherapy to immunotherapy
10.1038/s41571-023-00782-x · 2023 · External reference
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
10.1093/jnci/djad118 · 2023 · External reference
Radiation with immunotherapy may be a double-edged sword-how can we learn from recent negative clinical trials?
10.1001/jamaoncol.2024.1527 · 2024 · External reference
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer
10.1200/jco.2006.07.5937 · 2006 · External reference
Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies
10.1016/j.bpg.2016.07.003 · 2016 · External reference
Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma
10.1038/s41598-025-06909-7 · 2025 · External reference
Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1
10.1186/s12885-024-12313-7 · 2024 · External reference
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
10.1038/s41590-019-0561-4 · 2020 · External reference
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
10.1016/j.immuni.2014.10.019 · 2014 · External reference
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
10.1186/s13045-020-00940-z · 2020 · External reference
Dosimetric impact of esophagus motion in single fraction spine stereotactic body radiotherapy
10.1088/1361-6560/ab1c2b · 2019 · External reference
Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery
10.1007/s00066-020-01603-1 · 2020 · External reference
The multifunctional protein HMGB1: 50 years of discovery
10.1038/s41577-023-00894-6 · 2023 · External reference
HMGB1 silencing in macrophages prevented their functional skewing and ameliorated EAM development: nuclear HMGB1 may be a checkpoint molecule of macrophage reprogramming
10.1016/j.intimp.2018.01.013 · 2018 · External reference
HMGB1 coordinates SASP-related chromatin folding and RNA homeostasis on the path to senescence
10.15252/msb.20209760 · 2021 · External reference
Nuclear HMGB1 is critical for CD8 T cell IFN-gamma production and anti-tumor immunity
10.1016/j.celrep.2024.114591 · 2024 · External reference
O-GlcNAcylation enhances double-strand break repair, promotes cancer cell proliferation, and prevents therapy-induced senescence in irradiated tumors
10.1158/1541-7786.mcr-18-1025 · 2019 · External reference
PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer
10.1038/s41467-024-51242-8 · 2024 · External reference
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
2016 · External reference
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
10.1186/s12929-020-00670-x · 2020 · External reference
CXCR5(+) monocyte emigration impairs the radiation-induced antitumor immune response
10.1038/s41467-026-70858-6 · 2026 · External reference
Radiotherapy and immunology
10.1084/jem.20232101 · 2024 · External reference
Myeloid effector cells in cancer
10.1016/j.ccell.2024.11.002 · 2024 · External reference
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes
10.1158/0008-5472.can-09-4672 · 2010 · External reference
CCL2 (monocyte chemoattractant protein-1) and cancer
10.1016/j.semcancer.2003.10.009 · 2004 · External reference
Chemokines and the immune response to cancer
10.1016/j.immuni.2021.01.012 · 2021 · External reference
Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies
2025 · External reference
Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy
10.1016/j.semcancer.2021.04.002 · 2022 · External reference
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy
10.1172/jci.insight.130362 · 2020 · External reference
Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy
10.1016/j.ijrobp.2014.08.008 · 2014 · External reference
JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer
10.2217/fon-2018-0405 · 2019 · External reference
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
10.1016/s1470-2045(24)00100-1 · 2024 · External reference
Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study
10.1200/jco-25-00036 · 2025 · External reference
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
10.1038/nature00858 · 2002 · External reference
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
10.1038/nm1622 · 2007 · External reference
High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
10.1111/imr.12601 · 2017 · External reference
The mechanism of HMGB1 secretion and release
10.1038/s12276-022-00736-w · 2022 · External reference
Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer
10.1186/s10020-025-01235-0 · 2025 · External reference
Elevated mast cell abundance is associated with enrichment of CCR2+ cytotoxic T cells and favorable prognosis in lung adenocarcinoma
10.1158/0008-5472.can-22-3140 · 2023 · External reference
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
10.1136/gutjnl-2015-310514 · 2017 · External reference
CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
10.1186/s12943-020-01165-x · 2020 · External reference
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
10.1038/nature10138 · 2011 · External reference
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment
10.1158/0008-5472.can-11-1792 · 2012 · External reference
Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells
10.1016/j.celrep.2017.07.027 · 2017 · External reference
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer
10.1038/s41467-021-22618-x · 2021 · External reference
Radiation with immunotherapy may be a double-edged sword-how can we learn from recent negative clinical trials?
10.1001/jamaoncol.2024.1527 · ExternalCitation · doi-reference
Immunogenic cell death driven by radiation-impact on the tumor microenvironment
10.1007/978-3-030-38862-1_10 · ExternalCitation · doi-reference
Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery
10.1007/s00066-020-01603-1 · ExternalCitation · doi-reference
Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies
10.1016/j.bpg.2016.07.003 · ExternalCitation · doi-reference
Myeloid effector cells in cancer
10.1016/j.ccell.2024.11.002 · ExternalCitation · doi-reference
Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells
10.1016/j.celrep.2017.07.027 · ExternalCitation · doi-reference
Nuclear HMGB1 is critical for CD8 T cell IFN-gamma production and anti-tumor immunity
10.1016/j.celrep.2024.114591 · ExternalCitation · doi-reference
Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy
10.1016/j.ijrobp.2014.08.008 · ExternalCitation · doi-reference
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
10.1016/j.immuni.2014.10.019 · ExternalCitation · doi-reference
Chemokines and the immune response to cancer
10.1016/j.immuni.2021.01.012 · ExternalCitation · doi-reference
HMGB1 silencing in macrophages prevented their functional skewing and ameliorated EAM development: nuclear HMGB1 may be a checkpoint molecule of macrophage reprogramming
10.1016/j.intimp.2018.01.013 · ExternalCitation · doi-reference
CCL2 (monocyte chemoattractant protein-1) and cancer
10.1016/j.semcancer.2003.10.009 · ExternalCitation · doi-reference
Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy
10.1016/j.semcancer.2021.04.002 · ExternalCitation · doi-reference
Radiotherapy, immunity, and immune checkpoint inhibitors
10.1016/s1470-2045(24)00075-5 · ExternalCitation · doi-reference
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
10.1016/s1470-2045(24)00100-1 · ExternalCitation · doi-reference
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study
10.1016/s2214-109x(24)00355-3 · ExternalCitation · doi-reference
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
10.1038/nature00858 · ExternalCitation · doi-reference
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
10.1038/nature10138 · ExternalCitation · doi-reference
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
10.1038/nm1622 · ExternalCitation · doi-reference
The mechanism of HMGB1 secretion and release
10.1038/s12276-022-00736-w · ExternalCitation · doi-reference
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer
10.1038/s41467-021-22618-x · ExternalCitation · doi-reference
PD-L1 deglycosylation promotes its nuclear translocation and accelerates DNA double-strand-break repair in cancer
10.1038/s41467-024-51242-8 · ExternalCitation · doi-reference
CXCR5(+) monocyte emigration impairs the radiation-induced antitumor immune response
10.1038/s41467-026-70858-6 · ExternalCitation · doi-reference
Emerging evidence for adapting radiotherapy to immunotherapy
10.1038/s41571-023-00782-x · ExternalCitation · doi-reference
The multifunctional protein HMGB1: 50 years of discovery
10.1038/s41577-023-00894-6 · ExternalCitation · doi-reference
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
10.1038/s41590-019-0561-4 · ExternalCitation · doi-reference
Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma
10.1038/s41598-025-06909-7 · ExternalCitation · doi-reference
Radiotherapy and immunology
10.1084/jem.20232101 · ExternalCitation · doi-reference
Dosimetric impact of esophagus motion in single fraction spine stereotactic body radiotherapy
10.1088/1361-6560/ab1c2b · ExternalCitation · doi-reference
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
10.1093/jnci/djad118 · ExternalCitation · doi-reference
High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
10.1111/imr.12601 · ExternalCitation · doi-reference
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
10.1136/gutjnl-2015-310514 · ExternalCitation · doi-reference
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes
10.1158/0008-5472.can-09-4672 · ExternalCitation · doi-reference
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment
10.1158/0008-5472.can-11-1792 · ExternalCitation · doi-reference
Elevated mast cell abundance is associated with enrichment of CCR2+ cytotoxic T cells and favorable prognosis in lung adenocarcinoma
10.1158/0008-5472.can-22-3140 · ExternalCitation · doi-reference
O-GlcNAcylation enhances double-strand break repair, promotes cancer cell proliferation, and prevents therapy-induced senescence in irradiated tumors
10.1158/1541-7786.mcr-18-1025 · ExternalCitation · doi-reference
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy
10.1172/jci.insight.130362 · ExternalCitation · doi-reference
Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer
10.1186/s10020-025-01235-0 · ExternalCitation · doi-reference
Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1
10.1186/s12885-024-12313-7 · ExternalCitation · doi-reference
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
10.1186/s12929-020-00670-x · ExternalCitation · doi-reference
CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
10.1186/s12943-020-01165-x · ExternalCitation · doi-reference
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
10.1186/s13045-020-00940-z · ExternalCitation · doi-reference
Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study
10.1200/jco-25-00036 · ExternalCitation · doi-reference
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer
10.1200/jco.2006.07.5937 · ExternalCitation · doi-reference
HMGB1 coordinates SASP-related chromatin folding and RNA homeostasis on the path to senescence
10.15252/msb.20209760 · ExternalCitation · doi-reference
JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer
10.2217/fon-2018-0405 · ExternalCitation · doi-reference
